Patent 5476664 Issued on December 19, 1995. Estimated Expiration Date: April 15, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/443, Web, sheet or filament bases; compositions of bandages; or dressings with incorporated medicaments424/447, Bandages with incorporated medicaments424/448, Pressure sensitive adhesive means424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/938Oil-water type
A method of treating a patient having one or more warts includes the steps of: applying to the wart an amount of a composition consisting essentially of an anthralin active ingredient and a pharmaceutical carrier; covering the wart and skin areas peripheral to the wart with an adhesive tape, such that the adhesive tape adheres to peripheral skin areas, whereby the adhesive tape provides an occluding environment for the wart treated with the composition. The occluding environment is maintained for a desired period of time, and the adhesive tape is removed. For a number of times as desired, a fresh amount of anthralin-containing composition is applied, and a fresh piece of adhesive tape is applied to recreate the occluding environment.
Other References
Seville et al, "Dithranol cream", British Journal of Dermatology, (1979), vol. 100, pp. 475-476
Wilson et al, "Dithrocream in psoriasis", British Journal of Dermatology, (1980), vol. 102, pp. 105-106
Eriksen, "Treatment of the Common Wart by Induced Allergic Inflammation", Dermatologica, vol. 160, (1980), pp. 161-166
De Groot et al, "Contact allergy to dithranol" in Contact Dermatitis, vol. 7, pp. 5-8, 1981
Whitefield, "Pharmaceutical formulations of anthralin", in British Journal of Dermatology, (1981), vol. 105, Supplement 20, pp. 28-32
The Merck Index, Tenth Edition, (1983) for the entry "Anthralin"
Ashton et al entitled "Anthralin: Historical and Current Perspectives" in the Journal of the American Academy of Dermatology, vol. 9, No. 2, Aug. 1983, pp. 173-191
Franceschi et al, "Genital warts and cervical neoplasia: An epidemiological study", Br. J. Cancer, vol. 48, pp. 621-628, (1983)
Crum et al, "Human papillomavirus Type 16 and Early Cervical Neoplasia", The New England Journal of Medicine, vol. 310, No. 14, pp. 880-883, (Apr. 5, 1984)
Flindt-Hansen et al, "Wart Treatment With Anthralin", in Acta. Derm. Venereol. (Stockh.) 64: 177-180, 1984
Lowe et al entitled "Anthralin for psoriasis: Short-contact anthralin therapy compared with topical steroid and conventional anthralin", in Journal of the American Academy of Dermatology, vol. 10, No. 1, pp. 69-72, Jan. 1984
A brochure published by Dermik Laboratories, Inc. entitled "Anthralin Therapy Simplified", that accompanies the Drithocreme (™) product, includes text of a letter written by Nicholas J. Lowe, M.D., the same Dr. Lowe who coauthored the above-mentioned article
Hjorth et al entitled "Anthralin Stick (Anthraderm) in the Treatment of Mosaic Warts", in Acta. Derm. Venereol. (Stockh.) 66: 181-182, 1986
Mare et al, "Dithranol in the Treatment of Inflammatory Linear Verrucous Epidermal Nevus", in Acta Derm Venereol (Stockh), vol. 69 (Short Reports), pp. 77-80, (1989)
Kanerva, "Electron microscopic observations of dyskeratosis, apoptosis, colloid bodies and fibrillar degeneration after skin irritation with dithranol", in J. Cutan. Pathol., vol. 17, pp. 37-44, 1990
Rulo et al. "Treatment of Inflammatory Linear Verrucous Epidermal Nevus", Dermatologica, 1991, vol. 182, pp. 112-114
Vance, "Verruca Vulgaris (Warts)", pp. 743-745, in Conn's Current Therapy 1992, edited by Robert E. Rakel, M.D., W. B. Saunders Company, (1992)
Gottlieb et al entitled "Anthralin Decreases Keratinocyte TGF-alpha Expression and EGF-Receptor Binding in Vitro", in The Journal of Investigative Dermatology, vol. 98, No. 5, May 1992, pp. 680-685
Physicians' Desk Reference, 1993, under a listing for American Dermal Corporation, Plumsteadville, Pennsylvania 1894
April 15, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
